A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors
Trial details
- Registry ID
- NCT07656727
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk FactorsNCT07656727 | BIOA | Phase 2 | Active not recruiting | 2026-11-30Estimated |
| A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular EdemaNCT07812090 | BIOA | Phase 2 | Recruiting | 2027-11Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |